Pharmaceutical firm Seqirus has announced that its new therapy Ikervis is now available via the Pharmaceutical Benefits Scheme (PBS), making it Australia’s first listed disease modifying ciclosporin eye drop for severe keratitis in adults with dry eye disease (DED).
Pharmaceutical company Seqirus has announced that preservative-free dry eye therapy Cationorm is now accessible via the Pharmaceutical Benefits Scheme (PBS) in Australia. Read more
Allergan has secured regulatory approval for an alternative product to address a Prednefrin Forte shortage in Australia. Read more
The Therapeutic Goods Administration (TGA) has confirmed a shortage of Prednefrin Forte 10mL eye drops in Australia, which isn’t expected to be available until January next year, but its supplier has confirmed it is working towards providing an alternative product. Read more
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME). Read more
AFT Pharmaceuticals has officially introduced NovaTears + Omega-3 eye drops in Australia, and provided new details about the formulation. Read more
ASX-listed AFT Pharmaceuticals has expanded its therapeutics range with a new dry eye therapy containing Omega-3. Read more
Allergan’s Optive eye drops range, available in five varieties, includes Optive Advanced Preservative Free and Optive Advanced drops, which offer temporary relief of burning, irritation and discomfort due to dry eyes, and may protect against further irritation.
Preservative-free HYLO-FRESH (sodium K hyaluronate 0.1% w/v, 10mL), delivers lubrication for dry eyes of moderate or medium severity, while the more viscous HYLO-FORTE (0.2% sodium hyaluronate w/v, 10mL) is ideal for the treatment of severe or chronic dry eye.